US Patent

US8637079 — Solid preparation comprising alogliptin and pioglitazone

Formulation · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2029-06-04 · 3y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent provides a solid preparation containing alogliptin and pioglitazone, with improved dissolution and stability properties.

USPTO Abstract

A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts: (1) the first part containing compound (I) or a salt thereof and, as the first excipient, sugar or sugar alcohol; and (2) the second part containing pioglitazone or a salt thereof and, as the second excipient, sugar or sugar alcohol.

Drugs covered by this patent

Patent Metadata

Patent number
US8637079
Jurisdiction
US
Classification
Formulation
Expires
2029-06-04
Drug substance claim
No
Drug product claim
Yes
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.